Free CME from PeerView


Oncology CME

Credits: 1.0 CME / MOC / NCPD
Penn State College of Medicine
Mapping the Therapeutic Odyssey in Multiple Myeloma: Interprofessional Guidance on Evidence-Based Treatment Selection and Sequencing
Nina Shah, MD
May 09, 2022
Credits: 1.0 CME / MOC / CPE
Medical Learning Institute, Inc.
Making Sense of the Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy
Thomasina Morris, RPh, MHA, BCOP
May 06, 2022
Credits: 0.25 CME / CPE
Medical Learning Institute, Inc.
Making Sense of New Standards for CLL: Pharmacist Insights on Targeted Therapy and the Delivery of Team-Based Care
Amber C. King, PharmD, BCOP
May 06, 2022
Credits: 1.0 CME / MOC / CC / NCPD / CPE
Medical Learning Institute, Inc.
How to Harness Adjuvant CDK4 and 6 Inhibition to Prevent Recurrences in High-Risk HR+/HER2- Early Breast Cancer: New Goals and Better Tools to Close the Gaps
Erika Hamilton, MD
April 29, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Weighing the Evidence, Parsing the Practicalities: Integrating New Treatment Options Into the SCLC Treatment Arsenal to Improve Patient Outcomes in Oncology Practice
Jacob Sands, MD
April 27, 2022
Credits: 0.5 CME / MOC
PVI, PeerView Institute for Medical Education
Cancer Control Through Early Blood-Based Detection: Perspectives on Integrating Innovative Multicancer Early Detection Tests in the Primary Care Setting
John J. Russell, MD
April 22, 2022
Credits: 1.0 CME
PVI, PeerView Institute for Medical Education
Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC
Mark A. Socinski, MD
April 20, 2022
Credits: 1.25 CME
Medical Learning Institute, Inc.
Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management o
Henry M. Kuerer, MD, PhD, FACS
April 08, 2022
Credits: 0.5 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Dialing in the Dose: Reviewing Recent Evidence and Team-Based Strategies to Personalize and Optimize Patient Care in Metastatic Colorectal Cancer
Tanios Bekaii-Saab, MD
April 07, 2022
Credits: 0.5 CME / MOC / NCPD
Medical Learning Institute, Inc.
Solving the Challenge of Tumor Lysis Syndrome: Expert Insight and Guidance on a Challenging Oncologic Emergency
Anthony R. Mato, MD, MSCE
April 04, 2022
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations
Elizabeth Eaman, MD
April 01, 2022
Credits: 1.0 CME / MOC / NCPD / CPE
PVI, PeerView Institute for Medical Education
Primary Care Call to Action for VTE Management: Sharpening Skills in Recognition, Treatment, and Secondary Prevention
Geoffrey Barnes, MD, MSc
March 31, 2022
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
Kurt A. Schalper, MD, PhD
March 23, 2022
Credits: 1.5 CME / MOC / CC
Medical Learning Institute, Inc.
Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
Kurt A. Schalper, MD, PhD
March 22, 2022
Credits: 1.0 CME / MOC / NCPD
Medical Learning Institute, Inc.
When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
Bradley J. Monk, MD, FACS, FACOG
March 22, 2022
Henry M. Kuerer, MD, PhD, FACs / Heather L. McArthur, MD, MPH
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches
Henry M. Kuerer, MD, PhD, FACs / Heather L. McArthur, MD, MPH
March 12, 2022
Credits: 1.0 CME / MOC
Medical Learning Institute, Inc.
Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options
Jennifer Wargo, MD, MMSc
March 10, 2022
Credits: 0.5 CME
Medical Learning Institute, Inc.
Modern Management of ITP: Thinking Beyond the Conventional Therapies
Cindy Neunert, MD, MSCS
March 08, 2022
Credits: 1.0 CME / MOC
Medical Learning Institute, Inc.
Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
Nasser Altorki, MD / Jonathan D. Spicer, MD / PhD, FRCSC
February 22, 2022
Pasi A. Janne, MD, PhD
Credits: 1.0 CME / MOC
PVI, PeerView Institute for Medical Education
Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies
Pasi A. Janne, MD, PhD
February 22, 2022
Credits: 1.5 CME / MOC
Medical Learning Institute, Inc.
Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults
Robert Dreicer, MD, MS, MACP, FASCO
February 19, 2022
Credits: 1.5 CME / MOC
Medical Learning Institute, Inc.
Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies
Sumanta Kumar Pal, MD, FASCO
February 18, 2022
Credits: 1.5 CME / MOC
Medical Learning Institute, Inc.
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions
Petros Grivas, MD, PhD
February 18, 2022
Stephen V. Liu, MD
Credits: 0.75 CME / MOC
PVI, PeerView Institute for Medical Education
Visual Exploration of the Possibilities for Macrocyclic TKIs in Treatment-Naive and Pretreated Fusion-Positive NSCLC and Other Tumors
Stephen V. Liu, MD
February 18, 2022
Credits: 1.0 CME / MOC
Medical Learning Institute, Inc.
The Rising Tide of Novel BTK Inhibitors: Case-Based Guidance on Overcoming Intolerance, Resistance, and Other Clinical Challenges in B-Cell Cancers
Anthony R. Mato, MD, MSCE
February 17, 2022
Credits: 1.5 CME / MOC
Medical Learning Institute, Inc.
Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine
Milind Javle, MD
February 16, 2022
Credits: 1.5 CME / MOC
Medical Learning Institute, Inc.
Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
Richard S. Finn, MD
February 15, 2022
Boris Sepesi, MD, Tina Cascone, MD, PhD
Credits: 1.0 CME / MOC
Medical Learning Institute, Inc.
Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
Boris Sepesi, MD / Tina Cascone, MD / PhD
January 31, 2022
Erika Hamilton, MD
Credits: 1.0 CME
Medical Learning Institute, Inc.
Expanding Treatment Options in ER+/HER2- Breast Cancer: Expert Perspectives on the Rapidly Emerging Role of SERDs, SERMs, and SERCAs, and the Practical Considerations of Leveraging Established and Innovative Therapies
Erika Hamilton, MD
January 19, 2022
William D. Tap, MD
Credits: 0.25 CME / MOC
Medical Learning Institute, Inc.
Practice Points in TGCT: Updates on Safe Use of Novel Systemic Options
William D. Tap, MD
January 13, 2022

Pages

Upcoming Live Events

Education Collections

Recent CME Podcast

More Podcasts from PeerView